MXPA06008124A - Npc1l1 (npc3) y metodos para identificar ligandos del mismo. - Google Patents

Npc1l1 (npc3) y metodos para identificar ligandos del mismo.

Info

Publication number
MXPA06008124A
MXPA06008124A MXPA06008124A MXPA06008124A MXPA06008124A MX PA06008124 A MXPA06008124 A MX PA06008124A MX PA06008124 A MXPA06008124 A MX PA06008124A MX PA06008124 A MXPA06008124 A MX PA06008124A MX PA06008124 A MXPA06008124 A MX PA06008124A
Authority
MX
Mexico
Prior art keywords
npc1
cholesterol
binding
rat
npc1l1
Prior art date
Application number
MXPA06008124A
Other languages
English (en)
Spanish (es)
Inventor
Margarita Garcia-Calvo
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MXPA06008124A publication Critical patent/MXPA06008124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA06008124A 2004-01-16 2005-01-14 Npc1l1 (npc3) y metodos para identificar ligandos del mismo. MXPA06008124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53734104P 2004-01-16 2004-01-16
PCT/US2005/001469 WO2005069900A2 (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof

Publications (1)

Publication Number Publication Date
MXPA06008124A true MXPA06008124A (es) 2007-01-26

Family

ID=34807095

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06008124A MXPA06008124A (es) 2004-01-16 2005-01-14 Npc1l1 (npc3) y metodos para identificar ligandos del mismo.

Country Status (6)

Country Link
US (1) US7901893B2 (https=)
EP (1) EP1723414A4 (https=)
JP (1) JP4590417B2 (https=)
CA (1) CA2553769C (https=)
MX (1) MXPA06008124A (https=)
WO (1) WO2005069900A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
JP4590417B2 (ja) 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
US7696177B2 (en) * 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7910698B2 (en) 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EP2173893A4 (en) * 2007-06-28 2010-07-21 Merck Sharp & Dohme USE OF MDCK CELLS IN THE ASSESSMENT OF CHOLESTEROL MODULATORS
CN101580871B (zh) * 2008-05-13 2013-06-05 中国科学院上海生命科学研究院 基于分析npc1l1蛋白亚细胞定位变化筛选降胆固醇新药的方法
US8609098B2 (en) * 2010-06-10 2013-12-17 Adbiotech Co., Ltd. Composition for repression of hyperlipidemia and obesity through suppression of intestinal cholesterol absorption
US10377815B2 (en) 2015-05-05 2019-08-13 Albert Einstein College Of Medicine Bispecific antibodies and fusion proteins that bind to EBOV and NPC1

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2525125B2 (ja) * 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO1995001961A1 (en) * 1993-07-09 1995-01-19 Schering Corporation Process for the synthesis of azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1999001555A1 (en) * 1997-07-03 1999-01-14 The United States Of America Represented By The Secretary, Department Of Health And Human Services Genes for niemann-pick type c disease
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
EP1137634B1 (en) 1998-12-07 2005-06-15 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CA2367289C (en) 1999-04-05 2008-02-12 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1698697A3 (en) 2000-03-24 2006-09-13 Takeda Pharmaceutical Company Limited SSD-containing protein, process for producing the same and use thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1373230T3 (da) 2001-03-28 2005-11-07 Schering Corp Enantiselektiv syntese af azetidinon mellemprodukter
WO2003100094A2 (en) 2002-05-23 2003-12-04 Devgen Nv Method for determining the influence of a compound on cholesterol transport
CA2492017A1 (en) 2002-07-19 2004-01-29 Schering Corporation Npc1l1 (npc3) and methods of use thereof
US20040137467A1 (en) * 2002-07-19 2004-07-15 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
EP1529061B1 (en) 2002-08-06 2008-02-13 Sanofi-Aventis Deutschland GmbH Method for isolating an intestinal cholesterol binding protein
US20040171073A1 (en) 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
JP4590417B2 (ja) 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
EP1789437A4 (en) 2004-07-30 2008-11-05 Sinai School Medicine INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
WO2005069900A3 (en) 2006-06-08
EP1723414A4 (en) 2008-03-26
CA2553769A1 (en) 2005-08-04
WO2005069900A2 (en) 2005-08-04
EP1723414A2 (en) 2006-11-22
JP4590417B2 (ja) 2010-12-01
JP2007526998A (ja) 2007-09-20
WO2005069900B1 (en) 2006-08-03
US7901893B2 (en) 2011-03-08
US20100009461A1 (en) 2010-01-14
CA2553769C (en) 2011-01-04

Similar Documents

Publication Publication Date Title
MXPA06008124A (es) Npc1l1 (npc3) y metodos para identificar ligandos del mismo.
JP2010142238A (ja) Ｎｐｃ１ｌ１（ｎｐｃ３）およびその使用方法
JP2003513655A (ja) ２１個のヒト分泌タンパク質
JP2003528587A (ja) ２７個のヒト分泌タンパク質
US20120079616A1 (en) Npc1l1 (npc3) and methods of use thereof
JP2010252798A (ja) Ｎｐｃ１ｌ１（ｎｐｃ３）およびその使用方法
EP1293567B1 (en) Ligand to gpr8 and dna thereof
JP2003521242A (ja) １９個のヒト分泌タンパク質
US8212016B2 (en) NPC1L1 orthologues
WO2006098520A1 (ja) スクリーニング方法
US20040137467A1 (en) NPC1L1 (NPC3) and methods of use thereof
JP4693237B2 (ja) 脊椎動物ｐａｔｃｈｅｄ−２タンパク質
JP2003520032A (ja) ２４個のヒト分泌タンパク質
AU774958B2 (en) Fibroblast growth factor-5 (FGF-5) is a tumor associated T-cell antigen
JP2003532383A (ja) ヒトポリヌクレオチド、ポリペプチド、および抗体
JP4959880B2 (ja) Ｇｐｒ８に対するリガンドおよびそのｄｎａ
JP2003513663A (ja) ２４個のヒト分泌タンパク質
JP2003527829A (ja) ３８個のヒト分泌タンパク質
JP2003513668A (ja) ６個のヒト分泌タンパク質
JPWO2000032627A1 (ja) 新規生理活性物質、その製造法および用途

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NELSON M. KARP, M.D.